Purpose: The authors investigated the potential benefit of ingesting 2 mM of quinine (bitter tastant) on a 3000-m cycling time-trial (TT) performance. Methods: Nine well-trained male cyclists (maximal aerobic power: 386  W) performed a maximal incremental cycling ergometer test, three 3000-m familiarization TTs, and four 3000-m intervention TTs (∼4 min) on consecutive days. The 4 interventions were (1) 25 mL of placebo, (2) a 25-mL sweet solution, and (3) and (4) repeat 25 mL of 2-mM quinine solutions (Bitter1 and Bitter2), 30 s before each trial. Participants self-selected their gears and were only aware of distance covered. Results: Overall mean power output for the full 3000 m was similar for all 4 conditions: placebo, 348 (45) W; sweet, 355 (47) W; Bitter1, 354 (47) W; and Bitter2, 355 (48) W. However, quinine administration in Bitter1 and Bitter2 increased power output during the first kilometer by 15 ± 11 W and 21 ± 10 W (mean ± 90% confidence limits), respectively, over placebo, followed by a decay of 34 ± 32 W during Bitter1 and Bitter2 during the second kilometer. Bitter2 also induced a 11 ± 13-W increase during the first kilometer compared with the sweet condition. Conclusions: Ingesting 2 mM of quinine can improve cycling performance during the first one-third of a 3000-m TT and could be used for sporting events lasting ∼80 s to potentially improve overall performance.
Naroa Etxebarria, Megan L. Ross, Brad Clark and Louise M. Burke
Avish P. Sharma, Philo U. Saunders, Laura A. Garvican-Lewis, Brad Clark, Marijke Welvaert, Christopher J. Gore and Kevin G. Thompson
Purpose: To determine the effect of altitude training at 1600 and 1800 m on sea-level (SL) performance in national-level runners. Methods: After 3 wk of SL training, 24 runners completed a 3-wk sojourn at 1600 m (ALT1600, n = 8), 1800 m (ALT1800, n = 9), or SL (CON, n = 7), followed by up to 11 wk of SL racing. Race performance was measured at SL during the lead-in period and repeatedly postintervention. Training volume (in kilometers) and load (session rating of perceived exertion) were calculated for all sessions. Hemoglobin mass was measured via CO rebreathing. Between-groups differences were evaluated using effect sizes (Hedges g). Results: Performance improved in both ALT1600 (mean [SD] 1.5% [0.9%]) and ALT1800 (1.6% [1.3%]) compared with CON (0.4% [1.7%]); g = 0.83 (90% confidence limits −0.10, 1.66) and 0.81 (−0.09, 1.62), respectively. Season-best performances occurred 5 to 71 d postaltitude in ALT1600/1800. There were large increases in training load from lead-in to intervention in ALT1600 (48% [32%]) and ALT1800 (60% [31%]) compared with CON (18% [20%]); g = 1.24 (0.24, 2.08) and 1.69 (0.65, 2.55), respectively. Hemoglobin mass increased in ALT1600 and ALT1800 (∼4%) but not CON. Conclusions: Larger improvements in performance after altitude training may be due to the greater overall load of training in hypoxia compared with normoxia, combined with a hypoxia-mediated increase in hemoglobin mass. A wide time frame for peak performances suggests that the optimal window to race postaltitude is individual, and factors other than altitude exposure per se may be important.
Avish P. Sharma, Philo U. Saunders, Laura A. Garvican-Lewis, Brad Clark, Jamie Stanley, Eileen Y. Robertson and Kevin G. Thompson
To determine the effect of training at 2100-m natural altitude on running speed (RS) during training sessions over a range of intensities relevant to middle-distance running performance.
In an observational study, 19 elite middle-distance runners (mean ± SD age 25 ± 5 y, VO2max, 71 ± 5 mL · kg–1 · min–1) completed either 4–6 wk of sea-level training (CON, n = 7) or a 4- to 5-wk natural altitude-training camp living at 2100 m and training at 1400–2700 m (ALT, n = 12) after a period of sea-level training. Each training session was recorded on a GPS watch, and athletes also provided a score for session rating of perceived exertion (sRPE). Training sessions were grouped according to duration and intensity. RS (km/h) and sRPE from matched training sessions completed at sea level and 2100 m were compared within ALT, with sessions completed at sea level in CON describing normal variation.
In ALT, RS was reduced at altitude compared with sea level, with the greatest decrements observed during threshold- and VO2max-intensity sessions (5.8% and 3.6%, respectively). Velocity of low-intensity and race-pace sessions completed at a lower altitude (1400 m) and/or with additional recovery was maintained in ALT, though at a significantly greater sRPE (P = .04 and .05, respectively). There was no change in velocity or sRPE at any intensity in CON.
RS in elite middle-distance athletes is adversely affected at 2100-m natural altitude, with levels of impairment dependent on the intensity of training. Maintenance of RS at certain intensities while training at altitude can result in a higher perceived exertion.